The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2023A Novel Preclinical Candidate for Reducing Alpha-synuclein Aggregation in Parkinson’s Disease
Study Rationale: The goal of this program is to develop a novel drug for Parkinson’s disease (PD) with a unique mechanism of action. We have a drug candidate that shows potential as an inhibitor of...
-
Cellular Phenotyping in Human iPSCS from the PPMI Cohort, 2023Studying Microglia Produced from Cell Lines Obtained from the Parkinson’s Progression Markers Initiative
Study Rationale: We have previously studied how different genetic variants associated with Parkinson’s disease (PD) affect dopamine neurons, which are the brain cells that degenerate in this disease...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Characterizing Region-specific Lipid Profiles in Parkinson’s Disease and Gaucher Disease
Study Rationale: Mutations in the GBA1 gene, which encodes glucocerebrocidase (GCase), is the most prevalent risk factor for Parkinson’s disease (PD). The resulting deficit in GCase activity leads to...
-
Translational Pipeline Program, 2023Identifying Small Molecule Inducers of Autophagy and Lysosomes
Study Rationale: Neurons keep themselves healthy and free of damaged cellular materials using an internal garbage collection system called autophagy and internal recycling centers called lysosomes...
-
Research Grant, 2023Measuring Quality of Life in People with Parkinson’s Disease: State of the Art and Areas for Development
Study Rationale: Scales to measure quality of life are important tools for research. However, it is unclear whether currently available scales for measuring quality of life take into account the...
-
Therapeutic Pipeline Program, 2023Developing A Small-Molecule Activator of AMPK for the Treatment of Parkinson’s Disease
Study Rationale: Overwhelming evidence indicates that mitochondrial dysfunction contributes to the development of Parkinson’s disease (PD). We discovered that drugs that activate the enzyme AMPK...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.